Protein-based HIV-1 microbicides

Current HIV Research

Volumn 11, Issue 7, 2013, Pages 576-594

  Dey, Barna ^a   Lagenaur, Laurel A ^c,d   Lusso, Paolo ^b  

^a Laboratory of Viral Diseases   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Osel Inc   (United States)

Author keywords

Antiviral; Entry inhibitor; HIV; Lactobacillus; Live vector; Microbicide; Mucosal transmission; Prevention; Protein

Indexed keywords

CD4 ANTIBODY; CHEMOKINE RECEPTOR CCR; CYANOCOBALAMIN; CYANOVIRIN N; DEFENSIN; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GRIFFITHSIN; IBALIZUMAB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; INTEGRIN; LECTIN; MICROBICIDE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; PROSTAGLANDIN; PROTEIN BASED HIV 1 MICROBICIDE; RANTES; SIFUVIRTIDE; TIFUVIRTIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; PREVENTION AND CONTROL;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BIOLOGICAL PRODUCTS; DISEASE TRANSMISSION, INFECTIOUS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; LACTOBACILLUS; MICROBIOTA; RECOMBINANT PROTEINS;

EID: 84896337018     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X11666140101120709     Document Type: Article

References (234)

1. Weiss RA. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol 2008; 152(2): 201-10.
2. Dieffenbach CW, Fauci, AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011; 154(11): 766-71.
3. Nuttall J. Microbicides in the Prevention of HIV Infection Current Status and Future Directions. Drugs 2010; 70(10): 1231-43.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
5. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366(14): 1275-86.
6. Watkins DI, Update on progress in HIV vaccine development. Top Antivir Med 2012; 20(2): 30-1.
7. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Op HIV and AIDS 2010; 5: 428-34.
8. Kwong PD, JR. Mascola, GJ. Nabel, The changing face of HIV vaccine research. J Int AIDS Soc 2012; 15(2): 17407.
9. Valdiserri RO. Mapping the roots of HIV/AIDS complacency: Implications for program and policy development. Aids Education and Prevention 2004; 16(5): 426-39.
10. Valdiserri RO. A future free of HIV: What will it take? J Publ Health Manag Pract 2005; 11(1): 1-3.
11. Grant RM, Lama JR, AndersonPL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-99.
12. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9(2): 118-29.
13. Buckheit RW Jr, Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 2010; 85(1): 142-58.
14. Balzarini J, van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369(9563): 787-97.
15. Lederman MM, Jump R, Pilch-Cooper HA, Root M, Sieg SF. Topical application of entry inhibitors as virustats to prevent sexual transmission of HIV infection. Retrovirology 2008; 5, doi: 10.1186/1742-4690-5-116.
16. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012; 2(2): a007385.
17. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-74.
18. Abdool Karim SS, Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol 2012; 26(4): 427-39.
19. Klasse PJ, Shattock RJ, Moore JP. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006; 3(9): 1501-7.
20. Hillier SL Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo - the story of nonoxynol 9. J AIDS 2005; 39(1): 1-8.
21. Ndesendo VMK, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. Aaps Pharmsc 2008; 9(2): 505-20.
22. Woolfson AD., Malcolm RK, Gallagher R. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carr Syst 2000; 17(5): 509-55.
23. Pope M, Haase AT. Transmission, acute hiv-1 infection and the quest for strategies to prevent infection. Nat Med 2003; 9(7): 847-52.
24. Morrow G, Vachot L, Vagenas P, Robbiani M. Current concepts of HIV transmission. Curr HIV/AIDS Res 2007; 4(1): 29-35.
25. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6(1): 20-8.
26. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464(7286): 217-23.
27. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses 1998; 14: S119-23.
28. Khanna KV, Whaley KJ, Zeitlin L, et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 2002; 109(6): 205-11.
29. Teleshova NI, Frank MP. Immunodeficiency virus exploitation of dendritic cells in the early steps of infection. J Leukoc Biol 2003; 74(5): 683-90.
30. Geijtenbeek, TBH, van Kooyk Y. DC-SIGN: A novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 2003: 109(2); 31-54.
31. Derdeyn CA, Silvestri G. Viral and host factors in the pathogenesis of HIV infection. Curr Op Immunol 2005; 17(4): 366-73.
32. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6(2): 200-6.
33. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206(6): 1273-89.
34. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
35. Harouse JM, Tan RC, Gettie A, et al. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 1998; 248(1): 95-107.
36. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303(5666): 2019-22.
37. Li B, Decker JM, Johnson RW, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006; 80(11): 5211-8.
38. Rong R, Li B, Lynch RM, et al. Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways. PLoS Pathog 2009; 5(9): e1000594.
39. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1(8): 25-34.
40. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89. 6P in macaques. AIDS Res Hum Retroviruses 2003; 19(7): 535-41.
41. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20(1): 11-8.
42. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306(5695): 485-7.
43. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438(7064): 99-102.
44. Keele BF, Klasse PJ, Schader SM, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206(5): 1117-34.
45. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84(14): 7083-95.
46. Greenhead P Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74(12): 5577-86.
47. Shattock RJ, Griffin GE, Gorodeski GI, et al. In vitro models of mucosal HIV transmission. Nat Med 2000; 6(6): 607-8.
48. Hu Q, Frank I, Williams V, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199(8): 1065-75.
49. Harman S, Herrera C, Armanasco N, Nuttall J, Shattock RJ. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother 2012; 56(5): 2347-56.
50. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 2009; 90(Pt 1): 234-43.
51. O'Keefe BR, Vojdani F, Buffa V, et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 2009; 106(15): 6099-104.
52. Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, et al. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog 2012; 8(12): e1003071.
53. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191(9): 1403-9.
54. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6(5): e1000890.
55. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res 2003; 1(1): 69-86.
56. Harrison PF, Rosenberg Z, Bowcut J. Topical microbicides for disease prevention: status and challenges. Clin Infect Dis 2003; 36(10): 1290-4.
57. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of hiv infection. Curr Pharml Des 2004; 10(8): 315-36.
58. Masse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59: 455-71.
59. van Damme L, Taylor D. Cellulose Sulfate for Prevention of HIV Infection Reply. N Engl J Med 2008; 359(19): 2067-8.
60. Lagenaur LA, Sanders-Beer BE, Brichacek B, et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011; 4(6): 648-57.
61. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV Infection - 2004 recommendations of the International AIDS societyUSA panel. JAMA 2004; 292(3): 251-65.
62. Chang TL, Chang CH, Simpson DA, et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA 2003; 100(20): 11672-7.
63. Pusch O, Boden D, Hannify S, et al. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. JAIDS 2005; 40(5): 512-20.
64. Liu X, Lagenaur LA, Simpson DA, et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 2006; 50(10): 3250-9.
65. Pusch O, Kalyanaraman R, Tucker LD, et al. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 2006; 20(15): 1917-22.
66. Liu JJ, Reid G, Jiang Y, Turner MS, Tsai CC. Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol 2007; 9(1): 120-30.
67. Damelin LH, Mavri-Damelin D, Klaenhammer TR, Tiemessen CT. Plasmid transduction using bacteriophage Phi(adh) for expression of CC chemokines by Lactobacillus gasseri ADH. Appl Environ Microbiol 2010; 76(12): 3878-85.
68. Vangelista L, Secchi M, Liu X, et al. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob Agents Chemother 2010; 54(7): 2994-3001.
69. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280(5): 1884-8.
70. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. AnnuRev Biochem 2001; 70(34): 777-810.
71. Gallo SA, Finnegan CM, Viard M, et al. The HIV Env-mediated fusion reaction. Biochem Biophys Acta 2003; 1614(1): 36-50.
72. Lusso P. HIV and the chemokine system: 10 years later. EMBOJ 2006; 25(3): 447-56.
73. Este JA. Virus entry as a target for anti-HIV intervention. Curr Medic Chem 2003; 10: 1617-32.
74. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2003; 18(10): 685-93.
75. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004; 14(65): 255-70.
76. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-I. Immunol Today 1998; 19(1): 346-51.
77. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9(3): 301-9.
78. Domingue PA. The human vagina: normal flora considered as an in situ tissue-associated, adherent biofilm. Genitourin Med 1991; 67(3): 226-31.
79. Ravel J, Gajer P, Fu L, et al. Twice-daily application of HIV microbicides alter the vaginal microbiota. M Bio 2012; 3(6): e00370-12.
80. Boskey ER Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 2001; 16(9): 1809-13.
81. Hawes SE. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996; 174(5): 1058-63.
82. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180(6): 1863-8.
83. Taha TE, Gray RH, Kumwenda NI, et al. HIV infection and disturbances of vaginal flora during pregnancy. J AIDS 1999; 20(1): 52-9.
84. Rao S, Hu S, McHugh, et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA 2005; 102(34): 11993-8.
85. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15(8): 901-6.
86. Balazs AB, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481(7379): 81-4.
87. Abdel-Motal UM, Sarkis PT, Han T, et al. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One 2011; 6(10): e26473.
88. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004; 20: 247-53.
89. Brandtzaeg P, Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009; 70(6): 505-15.
90. Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JK. Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB Journal 2005; 19(14): 356-8.
91. Sexton A, Harman S, Shattock RJ, Ma JK. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 2009; 23(10): 3590-600.
92. Stiegler G, H Katinger. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother 2003; 51: 757-9.
93. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266(5187): 1024-7.
94. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445(7129): 732-7.
95. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70(2): 1100-8.
96. Saphire EO, Parren PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001; 293(5532): 1155-9.
97. Muster T, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67(11): 6642-7.
98. Ofek G, Tang M, Sambor A, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78(19): 10724-37.
99. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75(22): 10892-905.
100. Zwick MB, Jensen R, Church S, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79(2): 1252-61.
101. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004; 20(7): 755-62.
102. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75(17): 8340-7.
103. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5(5): e1000433.
104. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9(3): 343-6.
105. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108(27): 11181-6.
106. Hur EM, Patel SN, Shimizu S, et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012; 120(23): 4571-82.
107. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84(3): 1302-13.
108. Ferrantelli F, Rasmussen RA, Buckley KA, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189(12): 2167-73.
109. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2014; 7(1): 46-56.
110. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11(6): 615-22.
111. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16(2): 227-33.
112. Armbruster C, Stiegler GM, Vcelar BA, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004; 54(5): 915-20.
113. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458(7238): 636-40.
114. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453(7195): 667-71.
115. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993):856-61.
116. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333(6049): 1633-7.
117. Klein F, Gaebler C, Mouquet H, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 2012; 209(8): 1469-79.
118. Corti D, Langedijk JP, Hinz A, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5(1): e8805.
119. Veselinovic M, Neff CP, Mulder LR, Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012; 432(2): 505-10.
120. Seay K, Qi X, Zheng JH, et al. Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A new model for investigating HIV-1 transmission and treatment efficacy. PLoS One 2013; 8(5): e63537.
121. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285-9.
122. Bonsignori M, Hwang KK, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85(19): 9998-10009.
123. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477(7365): 466-70.
124. Xu L, Hué S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and - experienced patients. AIDS 2002; 16(12): 1684-6.
125. Reeves JD, Simmons G. Chemokine inhibition of HIV infection. Methods Mol Biol 2000; 138: 209-22.
126. Schneider SE, Bray BL, Mader CJ, et al. Development of HIV fusion inhibitors. J Pept Sci 2005; 11(11): 744-53.
127. Lalezari JP, Bellos NC, Sathasivam K, et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 2005; 191(7): 1155-63.
128. Martin-Carbonero L. Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev 2004; 6(1): 61.
129. He Y, Xiao Y, Song H, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008; 283(17): 11126-34.
130. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89(2): 263-73.
131. Eckert DM, PS. Kim. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001; 98(20): 11187-92.
132. Pappenheimer JR, Karnovsky ML, Maggio JE. Absorption and excretion of undegradable peptides: Role of lipid solubility and net charge. J Pharmacol Exp Ther 1997; 280(1): 292-300.
133. Welch BD, et al. Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance. J Virol 2010; 84(21): 11235-44.
134. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001; 291(5505): 884-8.
135. Steger HK, MJ. Root, Kinetic dependence to HIV-1 entry inhibition. J Biol Chem 2006; 281(35): 25813-21.
136. Kahle KM, Steger HK, Root MJ. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog 2009; 5(11): e1000674.
137. Daar ES, Ho DD. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am J Med 1991; 90: S22-S26.
138. Liu X, Lagenaur LA, Lee PP, Xu Q. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol 2008; 74(15): 4626-35.
139. Allaway GP, Davis-Bruno KL, Beaudry GA. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11(5): 533-9.
140. Trkola A, Ketas T, Kewalramani VN, et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998; 72(3): 1876-85.
141. Gauduin MC, Allaway GP, Olson WC, Weir R, Maddon PJ, Koup RA. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J Virol 1998; 72(4): 3475-8.
142. Shearer WT, Israel RJ, Starr S, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 2000; 182(6): 1774-9.
143. Jacobson JM, Israel RJ, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO542. Antimicrob Agents Chemother 2004; 48(2): 423-9.
144. Poignard P. Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibodylike molecule CD4-IgG2. PLoS One 2012; 7(7): e42209.
145. Chaikin M. Hexameric CD80 and CD86-Ig fusion proteins. J Allergy Clin Immunol 1997; 99(1): 835-9.
146. Arthos J, Cicala C, Steenbeke TD, et al. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem 2002; 277(13): 11456-64.
147. Vita C, Vizzavona J, Drakopoulou E, et al. Novel miniproteins engineered by the transfer of active sites to small natural scaffolds. Biopolymers 1998; 47(1): 93-100.
148. Martin L, Stricher F, Missé D, et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003; 21(1): 71-6.
149. Stricher F, Huang CC, Descours A, et al. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J Mol Biol 2008; 382(2): 510-24.
150. van Herrewege Y, Morellato L, Descours A, et al. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 2008; 61(4): 818-26.
151. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686): 648-59.
152. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201(9): 1407-19.
153. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003; 77(5): 2859-65.
154. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000; 74(1): 326-33.
155. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 2010; 7: 11.
156. West AP Jr, Galimidi RP, Foglesong CP, Gnanapragasam PN, Klein JS, Bjorkman PJ. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J Virol 2010; 84(1): 261-9.
157. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 2010; 88(1): 107-15.
158. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999; 96(5): 667-76.
159. Duma L, Häussinger D, Rogowski M, Lusso P, Grzesiek S. Recognition of RANTES by extracellular parts of the CCR5 receptor. J Mol Biol 2007; 365(4): 1063-75.
160. Veldkamp CT, Seibert C, Peterson FC, Sakmar TP, Volkman BF. Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1 alpha (SDF-1 alpha/CXCL12). J Mol Biol 2006; 359(5): 1400-9.
161. Cormier EG, Persuh M, Thompson DA, et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A 2000; 97(11): 5762-7.
162. Huang CC, Lam SN, Acharya P, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007; 317(5846): 1930-4.
163. Farzan M, Vasilieva N, Schnitzler CE, et al. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem 2000; 275(43): 33516-21.
164. Dorfman T, Moore MJ, Guth AC, Choe H, Farzan M. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 2006; 281(39): 28529-35.
165. Schnur E, Noah E, Ayzenshtat I, et al. The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide. J Mol Biol 2011; 410(5): 778-97.
166. Chiang JJ, Gardner MR, Quinlan BD, Dorfman T, Choe H, Farzan M. Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants. J Virol 2012; 86(22): 12417-21.
167. Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004; 103(4): 1211-7.
168. Dogo-Isonagie C, Lam S, Gustchina E, et al. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol Chem 2012; 287(18): 15076-86.
169. Massud I, Aung W, Martin A, et al. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol 2013; 87(16): 8952-61.
170. Jacobson JM, Lalezari JP, Thompson MA, et al. Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-infected Adults. Antimicrob Agents Chemother 2010; 54(10): 4137-42.
171. Burastero SE, Frigerio B, Lopalco L, et al. Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. PLoS One 2011; 6(7): e22081.
172. Hartley O, Gaertner H, Wilken J, et al. Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA 2004; 101(47): 16460-5.
173. Polo S, Nardese V, De Santis C, et al. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur J Immunol 2000; 30(11): 3190-8.
174. Vangelista L. M. Secchi, P Lusso, Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 2008; 26(24): 3008-5.
175. Jin H, Kagiampakis I, Li P, Liwang PJ. Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES. Proteins 2010; 78(2): 295-308.
176. Nomellini JF, Li C, Lavallee D, et al. Development of an HIV-1 specific microbicide using Caulobacter crescentus S-layer mediated display of CD4 and MIP1alpha. PLoS One 2010; 5(4): e10366.
177. Nardese V, Longhi R, Polo S, et al. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Biol 2001; 8(7): 611-5.
178. Lusso P, Vangelista L, Cimbro R, et al. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J 2011; 25(4): 1230-43.
179. Secchi M, Longhi R, Vassena L, et al. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides. Chem Biol 2012; 19(12): 1579-88.
180. Olson WC, Rabut GE, Nagashima KA, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73(5): 4145-55.
181. Roschke V, et al. Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV entry in 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004: Washington, DC. Abstract H-213.
182. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197(5): 721-7.
183. Ansari AA, Reimann KA, Mayne AE, et al. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011; 186(2): 1044-59.
184. Nawaz F, Cicala C, van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog 2011; 7(2): e1001301.
185. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393(6686): 705-11.
186. Lavine CL, et al. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol 2012; 86(4): 2153-64.
187. Geijtenbeek TB, Torensma R, van Vliet SJ, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100(5): 575-85.
188. Pöhlmann S, Baribaud F, Lee B, et al. DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol 2001; 75(10): 4664-72.
189. Mummidi S, Catano G, Lam L, et al. Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms. Inter-individual variation in expression of DC-SIGN transcripts. J Biol Chem 2001; 276(35): 33196-212.
190. Mitchell DA, Fadden AJ, Drickamer K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 2001; 276(31): 28939-45.
191. Hijazi K, Wang Y, Scala C, et al. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One 2011; 6(12): e28307.
192. Du T, Hu K, Yang J, et al. Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination. Antimicrob Agents Chemother 2012; 56(9): 4640-9.
193. Wang Q, Pang S. An intercellular adhesion molecule-3 (ICAM-3)-grabbing nonintegrin (DC-SIGN) efficiently blocks HIV viral budding. FASEB J 2008; 22(4): 1055-64.
194. Turville SG, Cameron PU, Arthos J, et al. Bitter-sweet symphony: defining the role of dendritic cell gp120 receptors in HIV infection. J Clin Virol 2001; 22(3): 229-39.
195. Nabatov AA, de Jong MA, de Witte L, Bulgheresi S, Geijtenbeek TB, et al. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells. Virology 2008; 378(2): 323-8.
196. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41(7): 1521-30.
197. Gustafson KR, Sowder RC II, Henderson LE, et al. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun 1997; 238(1): 223-8.
198. Shenoy SR, O'Keefe BR, Bolmstedt AJ, Cartner LK, Boyd MR. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther 2001; 297(2): 704-10.
199. Bolmstedt AJ, O'Keefe BR, Shenoy SR, McMahon JB, Boyd MR. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol 2001; 59(5): 949-54.
200. Bewley CA, Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man (8) D1D3 and Man (9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J Am Chem Soc 2001; 123(17): 3892-902.
201. Esser MT, Mori T, Mondor I, et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 1999; 73(5): 4360-71.
202. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 2000; 74(10): 4562-9.
203. Giomarelli B, Provvedi R, Meacci F, et al. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 2002; 16(10): 1351-6.
204. Mori T, O'Keefe BR, Sowder RC II, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280(10): 9345-53.
205. Huang X, Jin W, Griffin GE, Shattock RJ, Hu Q. Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J Gen Virol 2011; 92(Pt 10): 2367-73.
206. Emau P, Tian B, O'keefe BR, et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 2007; 36(4-5): 244-53.
207. Kagiampakis I, Gharibi A, Mankowski MK, et al. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. Antimicrob Agents Chemother 2011; 55(1): 264-75.
208. Bokesch HR, O'Keefe BR, McKee TC, et al. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 2003; 42(9): 2578-84.
209. Xiong C, O'Keefe BR, Byrd RA, McMahon JB. Potent anti-HIV activity of scytovirin domain 1 peptide. Peptides 2006; 27(7): 1668-75.
210. Alexandre KB, Gray ES, Mufhandu H, et al. The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 2012; 423(2): 175-86.
211. Huskens D, Férir G, Vermeire K, et al. Microvirin, a novel {alpha}(1,2)-mannose-specific lectin isolated from microcystis aeruginosa, has comparable anti-HIV-1 activity as cyanovirin-N, but a much higher safety profile. J Biol Chem 2010; 285(32): 24845-54.
212. Shahzad-ul-Hussan S, Gustchina E, Ghirlando R, Clore GM, Bewley CA. Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1-2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem 2011; 286(23): 20788-96.
213. Koshte VL, van Dijk W, van der Stelt ME, Aalberse RC. Isolation and characterization of BanLec-I, a mannoside-binding lectin from Musa paradisiac (banana). Biochem J 1990; 272(3): 721-6.
214. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM. A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem 2010; 285(12): 8646-55.
215. Lehrer RI. Primate defensins. Nat Rev Microbiol 2004; 2(9): 727-38.
216. Quiñones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17(16): F39-F48.
217. Seidel A, Ye Y, de Armas LR, et al. Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms. PLoSOne 2010; 5(3); e9737.
218. Furci L, Sironi F, Tolazzi M, et al. Blood 2007; 109(7): 2928-35.
219. Münk C, Wei G, Yang OO, et al. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses 2003; 19(10): 875-81.
220. Furci L, Tolazzi M, Sironi F, et al. Inhibition of HIV-1 infection by human alpha-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae. PLoS One 2012; 7(9): e45208.
221. Wu Z, Cocchi F, Gentles D, et al. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro. FEBS Letters 2005; 579(1): 162-6.
222. Cole AM, Hong T, Boo LM, et al. Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002; 99(4): 1813-8.
223. Owen SM, Rudolph DL, Wang W, et al. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2004; 20(11): 1157-65.
224. Venkataraman N, Cole AL, Ruchala P, et al. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol 2009; 7(4): e95.
225. Pouwels PH, Leunissen JA. Leunissen, Divergence in codon usage of Lactobacillus species. Nucleic Acids Res 1994; 22(6): 929-36.
226. Yu RR, Cheng AT, Lagenaur LA, et al. A Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development. J Med Primatol 2009; 38(2): 125-36.
227. Patton DL, Kidder GG, Sweeney YC, et al. Effects of nonoxynol-9 on vaginal microflora and chlamydial infection in a monkey model. Sex Transm Dis 1996; 23(6): 461-4.
228. Mirmonsef P, Gilbert D, Veazey RS, et al. A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility. AIDS Res Hum Retroviruses 2012; 28(1): 76-81.
229. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350(9077): 546-50.
230. Martinez RC, Seney SL, Summers KL, et al. Effect of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and induce inflammation. Microbiol Immunol 2009; 53(9): 487-95.
231. Macho Fernandez E, Valenti V, Rockel C, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011; 60(8): 1050-9.
232. Yamamoto HS, Xu Q, Fichorova RN. Fichorova, Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC Microbiol 2013; 13: 4.
233. Ross JJ, Boucher PE, Bhattacharyya SP, et al. Considerations in the development of live biotherapeutic products for clinical use. Curr Issues Mol Biol 2008; 10(1-2): 13-6.
234. Moncla BJ, Pryke K, Rohan LC, Yang H. Testing of viscous anti-HIV microbicides using Lactobacillus. J Microbiol Methods 2012; 88(2): 292-6.